Xilio Therapeutics, Inc. XLO

Xilio Therapeutics released second quarter 2026 financial results and provided pipeline and business updates. Quarterly results plus pipeline updates can moderately shift near-term sentiment and operational outlook.

Xilio Therapeutics, Inc. (XLO) reported a Q1 loss but beat revenue estimates. Q1 revenue beat despite expected loss moderately boosts short-term sentiment and financial perception without transforming long-term outlook.

Xilio Therapeutics reported first quarter 2026 financial results and provided updates on its pipeline and business activities. Quarterly financial results directly affect financial performance metrics, while pipeline updates influence competitive positioning and investor sentiment.

Xilio Therapeutics presented new preclinical data at the AACR Annual Meeting for XTX601, a tumor-activated masked T cell engager targeting CLDN18.2, demonstrating potent anti-tumor activity in gastric cancer models, complete tumor regression in some cases, and minimal cytokine release or systemic toxicity compared to unmasked versions. Preclinical data strengthens pipeline in gastric cancer but lacks clinical proof to drive major trajectory shifts.

Xilio Therapeutics (XLO) upgraded to Buy rating by analysts, signaling potential upside for the stock amid evaluation of its implications. Analyst upgrade to Buy poised to significantly boost investor sentiment and alter short-term stock trajectory.

Xilio Therapeutics (XLO) upgraded to Buy rating by analysts, potentially signaling positive stock momentum amid evaluation of implications for future performance. Analyst upgrade to Buy expected to moderately boost investor sentiment and short-term stock performance without fundamental changes.

Xilio Therapeutics announces pipeline and business updates alongside fourth quarter and full-year 2025 financial results. Pipeline updates and financial results disclosure affects key financial performance and investor sentiment.

Xilio Therapeutics will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting. Presentation of new preclinical data highlights pipeline advancement in oncology, likely generating moderate investor interest and influencing short-to-medium term sentiment.

Xilio Therapeutics, Inc. (XLO) announced a 1-for-14 reverse stock split to reduce outstanding shares and boost the per-share price, likely to meet Nasdaq listing requirements. The 1-for-14 reverse stock split signals potential financial distress and compliance issues, significantly harming investor sentiment and stock trajectory.

Xilio Therapeutics, Inc. has announced the pricing of an underwritten public offering of its common stock, aiming to raise approximately $15 million. The offering consists of 3 million shares priced at $5.00 per share. The company intends to use the proceeds for general corporate purposes, including advancing its clinical programs and working capital. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The capital raised may support clinical programs and operational needs, influencing financial performance moderately.

Xilio Therapeutics, Inc. provided updates on its upcoming milestones and recent corporate developments, highlighting progress in its clinical programs and strategic initiatives aimed at enhancing its market position and operational efficiency. Significant strategic moves and clinical advancements are expected to impact the company's future performance and investor sentiment.

Xilio Therapeutics, Inc. (XLO) provided updates on its pipeline and business operations alongside its financial results for the third quarter of 2025. The company highlighted advancements in its therapeutic candidates and outlined strategic initiatives aimed at enhancing its market position. Financial results indicated progress in revenue generation and investment in research and development, reflecting the company's commitment to innovation in the biopharmaceutical sector. Significant advancements in the pipeline and strategic initiatives are likely to impact future performance and investor sentiment.

Xilio Therapeutics, Inc. announced late-breaking Phase 2 data for Vilastobart, targeting patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and high plasma tumor mutational burden. The data was presented at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting the potential of Vilastobart in this patient population. The presentation of significant Phase 2 data could lead to increased interest and investment in Xilio's therapeutic pipeline.

Xilio Therapeutics, Inc. showcased its portfolio of differentiated masked immunotherapies at the Society for Immunotherapy of Cancer's 40th Annual Meeting. The presentation highlighted the company's innovative approach to enhancing the efficacy and safety of immunotherapy treatments, aiming to improve patient outcomes in cancer care. The presentation of differentiated immunotherapies could significantly influence Xilio's competitive positioning and investor sentiment in the oncology market.

Xilio Therapeutics, Inc. (XLO) will present Phase 2 data for Vilastobart at the SITC 40th Annual Meeting, focusing on response rates in patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC) and high plasma tumor mutational burden. This late-breaking presentation highlights the potential efficacy of Vilastobart in a specific patient population, which could influence future treatment options and market interest. The presentation of Phase 2 data could significantly impact investor sentiment and the company's strategic positioning in the oncology market.

Xilio Therapeutics, Inc. (XLO) announced its upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, highlighting its commitment to advancing immunotherapy research and showcasing its innovative approaches in cancer treatment. Presentations at a major conference can enhance visibility and credibility, potentially influencing investor sentiment and future collaborations.

Xilio Therapeutics, Inc. has initiated a Phase 2 trial for Efarindodekin Alfa (XTX301), a tumor-activated IL-12 therapy. Additionally, the company achieved a $17.5 million development milestone under its exclusive license agreement with Gilead. The initiation of a Phase 2 trial and the milestone achievement are significant developments that could enhance the company's market position and investor sentiment.

Xilio Therapeutics, Inc. (XLO) provided updates on its pipeline and business operations alongside its financial results for the second quarter of 2025. The company highlighted advancements in its therapeutic candidates and outlined strategic initiatives aimed at enhancing its market position. Financial results indicated progress in revenue generation and investment in research and development, reflecting the company's commitment to innovation in the biopharmaceutical sector. Significant advancements in the pipeline and strategic initiatives are likely to impact future performance and investor sentiment.

Xilio Therapeutics, Inc. (XLO) reported a loss for Q2, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it continues to navigate challenges in its operational strategy and market positioning. The missed revenue estimates indicate potential challenges in financial performance and market sentiment.

Bristol Myers Squibb and Bain Capital have announced the formation of a new immunology company, which will focus on developing innovative therapies in the immunology space. This strategic move aims to leverage Bristol Myers Squibb's expertise in drug development and Bain Capital's investment capabilities to accelerate advancements in immunology treatments. The partnership is expected to enhance the competitive landscape in the biopharmaceutical sector, particularly in immunology. The formation of a new immunology company could moderately influence the competitive landscape and innovation in the sector, impacting Xilio Therapeutics' positioning.

Xilio Therapeutics, Inc. has appointed Akintunde Bello, Ph.D., to its Board of Directors, enhancing its leadership team with his extensive experience in drug development and commercialization. Dr. Bello has held significant roles in various biopharmaceutical companies and is expected to contribute to Xilio's strategic direction and growth. The appointment of a seasoned professional to the board may positively influence the company's strategic direction and operational effectiveness.

Xilio Therapeutics, Inc. has closed a public offering of pre-funded warrants and common stock warrants, generating approximately $50 million in gross proceeds. If all Series B and Series C warrants are exercised, the company could receive an additional $100 million by the end of 2026, totaling up to $150 million. The financing was co-led by Coastlands Capital and Frazier Life Sciences, with participation from Gilead Sciences and other investors. The proceeds will be used to advance product development and for general corporate purposes. The financing significantly enhances Xilio's capital position, enabling further development of its product candidates and potentially altering its market trajectory.

Xilio Therapeutics, Inc. announced a public offering of pre-funded warrants and various series of warrants to purchase a total of 66,676,000 shares of common stock, priced at $0.7499 each, aiming to raise approximately $50 million. The offering is expected to close around June 5, 2025, pending customary conditions. The proceeds will be used for product development and general corporate purposes. If all warrants are exercised, Xilio could receive up to an additional $100 million. Leerink Partners is the sole bookrunner for the offering. The public offering and potential additional proceeds could significantly enhance Xilio's financial resources for product development and operational needs.

Xilio Therapeutics, Inc. announced a proposed underwritten public offering of pre-funded warrants and various series of warrants to purchase shares of common stock. The offering is subject to market conditions, and proceeds will be used to advance product development and for general corporate purposes. Leerink Partners is the sole bookrunner for the offering, which is registered under a previously filed shelf registration statement. A preliminary prospectus supplement will be filed with the SEC. The public offering may provide necessary funding for product development, impacting financial performance and innovation.

Xilio Therapeutics, Inc. announced updated Phase 2 data for Vilastobart, a tumor-activated anti-CTLA-4 therapy, in combination with Atezolizumab for patients with metastatic microsatellite stable colorectal cancer. The data demonstrated promising efficacy and safety profiles, suggesting potential for improved treatment outcomes in this patient population. The company aims to further develop this combination therapy as part of its oncology pipeline. The updated Phase 2 data indicates significant potential for Vilastobart, which could enhance Xilio's competitive positioning and investor sentiment.

Xilio Therapeutics, Inc. reported pipeline progress and Q1 2025 financial results, highlighting a 27% objective response rate for vilastobart in combination with atezolizumab for metastatic microsatellite stable colorectal cancer. The company is advancing multiple masked T cell engager programs and plans to present updated Phase 2 data at the ASCO meeting. Xilio's cash position improved to $89.1 million, bolstered by a $52 million collaboration agreement with AbbVie. R&D expenses decreased to $8.3 million, while G&A expenses rose to $8.5 million, resulting in a net loss of $13.3 million for the quarter. The collaboration with AbbVie and promising clinical data for vilastobart are likely to significantly impact Xilio's future performance and market sentiment.

Xilio Therapeutics, Inc. will present updated Phase 2 data for Vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 therapy, in combination with Atezolizumab for patients with microsatellite stable colorectal cancer at the 2025 ASCO Annual Meeting. The presentation of updated Phase 2 data could significantly influence investor sentiment and the company's strategic direction in oncology.

Xilio Therapeutics, Inc. reported pipeline advancements and financial results for Q4 and full year 2024. Initial Phase 2 data for vilastobart, an anti-CTLA-4 therapy, showed a 27% objective response rate in MSS CRC patients without liver metastases. The company is advancing masked T cell engager programs and announced a collaboration with AbbVie, receiving $52 million in upfront payments. Xilio's cash position improved to $55.3 million, and it expects to fund operations into Q1 2026. R&D expenses decreased, while net loss for Q4 was $13.1 million, down from $17.7 million in Q4 2023. The collaboration with AbbVie and promising clinical data for vilastobart are likely to significantly impact Xilio's future performance and market sentiment.

Xilio Therapeutics, Inc. (XLO) reported a loss for Q4 that exceeded analysts' expectations, leading to a revenue shortfall. The company's financial performance has raised concerns among investors, as it continues to struggle in meeting revenue estimates. This disappointing report may impact investor sentiment and the company's future market performance. The Q4 loss and revenue lag may moderately influence investor sentiment and financial performance, but the overall effect is expected to be somewhat limited.

AbbVie has partnered with Xilio Therapeutics to develop tumour-activated, antibody-based immunotherapies, including masked T-cell engagers. Xilio will receive $52 million upfront, with potential payments up to $2.1 billion. The collaboration aims to leverage AbbVie's oncology expertise and Xilio's tumour-activation technology to enhance next-generation immunotherapies while minimizing systemic adverse events. AbbVie is focused on expanding its oncology research, following a previous partnership with Neomorph for molecular glue degraders. The collaboration with AbbVie is expected to significantly enhance Xilio's product development and market positioning in oncology.